Clinical Management of Patients With Advanced Parkinson’s Disease Treated With Continuous Intestinal Infusion of levodopa/carbidopa

References

• Duodopa . Summary of Product Characteristicswww.medicines.org.uk/emc/medicine/20786
   Google Scholar
• Nyholm D , AskmarkH, Gomes-TrolinCet al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets . Clin. Neuropharmacol.26 ( 3 ), 156 – 163 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D , Nilsson RemahlAI, DizdarNet al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease . Neurology64 ( 2 ), 216 – 223 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Palhagen SE , DizdarN, HaugeTet al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease . Acta Neurol. Scand.126 ( 6 ), e29 – e33 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Antonini A , IsaiasIU, CanesiMet al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12 month treatment outcome . Mov. Disord.22 ( 8 ), 1145 – 1149 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Antonini A , YeginA, PredaCet al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12 month interim outcomes . Parkinsonism Relat. Disord.21 ( 3 ), 231 – 235 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Devos D , FrenchDSG . Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease . Mov. Disord.24 ( 7 ), 993 – 1000 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Eggert K , SchraderC, HahnMet al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications . Clin. Neuropharmacol.31 ( 3 ), 151 – 166 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Elia AE , DollenzC, SoliveriP, AlbaneseA . Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation . Eur. J. Neurol.19 ( 1 ), 76 – 83 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Fernandez HH , StandaertDG, HauserRAet al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12 month, open-label results . Mov. Disord.30 ( 4 ), 500 – 509 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fernandez HH , VanagunasA, OdinPet al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results . Parkinsonism Relat. Disord.19 ( 3 ), 339 – 345 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Isacson D , BingeforsK, KristiansenIS, NyholmD . Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion . Acta Neurol. Scand.118 ( 6 ), 379 – 386 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kurth MC , TetrudJW, TannerCMet al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson’s disease patients with ‘on-off’ fluctuations . Neurology43 ( 9 ), 1698 – 1703 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P , ReddyP, KatzenschlagerRet al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease . Mov. Disord.30 ( 4 ), 510 – 516 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Meppelink AM , NymanR, Van LaarT, DrentM, PrinsT, LeendersKL . Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson’s disease . Mov. Disord.26 ( 2 ), 331 – 334 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Merola A , ZibettiM, AngrisanoS, RizziL, LanotteM, LopianoL . Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease . Mov. Disord.26 ( 4 ), 664 – 670 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Munro Neville A , ParsonsRW, AskmarkH, NyholmD . Treatment of advanced Parkinson’s disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage . Parkinsonism Relat. Disord.18 ( 5 ), 686 – 687 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nilsson D , HanssonLE, JohanssonK, NystromC, PaalzowL, AquiloniusSM . Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson’s disease . Acta Neurol. Scand.97 ( 3 ), 175 – 183 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Nilsson D , NyholmD, AquiloniusSM . Duodenal levodopa infusion in Parkinson’s disease – long-term experience . Acta Neurol. Scand.104 ( 6 ), 343 – 348 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D . Duodopa(R) treatment for advanced Parkinson’s disease: a review of efficacy and safety . Parkinsonism Relat. Disord.18 ( 8 ), 916 – 929 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D , JohanssonA, LennernasH, AskmarkH . Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial . Eur. J. Neurol.19 ( 6 ), 820 – 826 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D , KlangemoK, JohanssonA . Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson’s disease . Eur. J. Neurol.19 ( 8 ), 1079 – 1085 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D , LewanderT, JohanssonA, LewittPA, LundqvistC, AquiloniusSM . Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure . Clin. Neuropharmacol.31 ( 2 ), 63 – 73 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Olanow CW , KieburtzK, OdinPet al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study . Lancet Neurol.13 ( 2 ), 141 – 149 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Puente V , De FabreguesO, OliverasCet al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson’s disease: impact on control of fluctuations and quality of life . Parkinsonism Relat. Disord.16 ( 3 ), 218 – 221 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Reddy P , Martinez-MartinP, RizosAet al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects . Clin. Neuropharmacol.35 ( 5 ), 205 – 207 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D , MaciasM, LlanezaMet al. Experience with continuous levodopa enteral infusion (Duodopa((R))) in patients with advanced Parkinson’s disease in a secondary level hospital . Neurologia25 ( 9 ), 536 – 543 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Sensi M , PredaF, TrevisaniLet al. Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients . J. Neural. Transm. (Vienna)121 ( 6 ), 633 – 642 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Slevin JT , FernandezHH, ZadikoffCet al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients . J. Parkinsons Dis.5 ( 1 ), 165 – 174 ( 2015 ).
   PubMedGoogle Scholar
• Syed N , MurphyJ, ZimmermanTJr, MarkMH, SageJI . Ten years’ experience with enteral levodopa infusions for motor fluctuations in Parkinson’s disease . Mov. Disord.13 ( 2 ), 336 – 338 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Timpka J , FoxT, FoxKet al. Improvement of dyskinesias with l-dopa infusion in advanced Parkinson’s disease . Acta Neurol. Scand. doi:10.1111/ane.12483 ( 2015 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Antonini A , FungVS, BoydJTet al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients . Mov. Disord. doi:10.1002/mds.26528 ( 2016 ) ( Epub ahead of print ).
   Google Scholar
• Buongiorno M , AntonelliF, CámaraAet al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry . Parkinsonism Relat. Disord.21 ( 8 ), 871 – 876 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Honig H , AntoniniA, Martinez-MartinPet al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life . Mov. Disord.24 ( 10 ), 1468 – 1474 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Pursiainen V , LyytinenJ, PekkonenE . Effect of duodenal levodopa infusion on blood pressure and sweating . Acta Neurol. Scand.126 ( 4 ), e20 – e24 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zibetti M , MerolaA, RicchiVet al. Long-term duodenal levodopa infusion in Parkinson’s disease: a 3 year motor and cognitive follow-up study . J. Neurol.260 ( 1 ), 105 – 114 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Antonini A , ManciniF, CanesiMet al. Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease . Neurodegener. Dis.5 ( 3–4 ), 244 – 246 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D , SanjurjoLF, MaciasM, LlanezaM, CarpinteroP, De La Fuente-FernandezR . Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being . Acta Neurol. Scand.125 ( 3 ), 187 – 191 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Daniel SE , LeesAJ . Parkinson’s Disease Society Brain Bank, London: overview and research . J. Neural. Transm. Suppl.39, 165 – 172 ( 1993 ).
   PubMedGoogle Scholar
• Committee ASOP , AndersonMA, Ben-MenachemTet al. Management of antithrombotic agents for endoscopic procedures . Gastrointest. Endosc.70 ( 6 ), 1060 – 1070 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kempster PA , WilliamsDR, SelikhovaM, HoltonJ, ReveszT, LeesAJ . Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study . Brain130 ( Pt 8 ), 2123 – 2128 ( 2007 ).
   PubMedGoogle Scholar
• Calandrella D , RomitoLM, EliaAEet al. Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease . Neurology84 ( 16 ), 1669 – 1672 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Antonini A , OdinP . Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson’s disease . Parkinsonism Relat. Disord.15 ( Suppl. 4 ), S97 – S100 ( 2009 ).
   PubMedGoogle Scholar
• Sanchez-Castaneda C , CampdelacreuJ, MiroJ, JuncadellaM, JaumaS, CalopaM . Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson’s disease patients . Prog. Neuropsychopharmacol. Biol. Psychiatry34 ( 1 ), 250 – 251 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Catalan MJ , De Pablo-FernandezE, VillanuevaCet al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson’s disease . Mov. Disord.28 ( 14 ), 2007 – 2010 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Todorova A , SamuelM, BrownRG, ChaudhuriKR . Infusion therapies and development of impulse control disorders in advanced Parkinson’s disease: clinical experience after 3 years’ follow-up . Clin. Neuropharmacol.38 ( 4 ), 132 – 134 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Volkmann J , AlbaneseA, AntoniniA . Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review . J. Neurol.260 ( 11 ), 2701 – 2714 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Odin P , Ray ChaudhuriKet al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program . Parkinsonism Relat. Disord.21 ( 10 ), 1133 – 1144 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Tomlinson CL , StoweR, PatelS, RickC, GrayR, ClarkeCE . Systematic review of levodopa dose equivalency reporting in Parkinson’s disease . Mov. Disord.25 ( 15 ), 2649 – 2653 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Extracts from Practical guidelines for the treatment of advanced Parkinson’s disease using continuousintestinal infusion of levodopa/carbidopa (Duodopa®). www.contentednet.com/projects/duodopa-guidelines/
   Google Scholar
• Santos-Garcia D , AnonMJ, Fuster-SanjurjoL, De La Fuente-FernandezR . Duodenal levodopa/carbidopa infusion therapy infusion in patients with advanced Parkinson’sdisease leads to improvement in caregivers’ stress and burden . Eur. J. Neurol.19 ( 9 ), 1261 – 1265 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Solla P , FasanoA, CannasAet al. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson’s disease patients treatedwith levodopa-carbidopa intestinal gel infusion . Parkinsonism Relat. Disord.21 ( 8 ), 968 – 971 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Meiler B , AndrichJ, MullerT . Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion . Mov. Disord.23 ( 1 ), 145 – 146 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Pearce CB , DuncanHD . Enteral feeding. Nasogastric, nasojejunal, percutaneous endoscopic gastrostomy, or jejunostomy: its indications and limitations . Postgrad. Med. J.78 ( 918 ), 198 – 204 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Pedersen SW , ClausenJ, GregerslundMM . Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic . Open Neurol. J.6, 37 – 50 ( 2012 ).
   PubMedGoogle Scholar
• Wenzelburger R , ZhangBR, PohleSet al. Force overflow and levodopa-induced dyskinesias in Parkinson’s disease . Brain125 ( Pt 4 ), 871 – 879 ( 2002 ).
   PubMedGoogle Scholar
• Chang FC , TsuiDS, MahantNet al. 24 h Levodopa-carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson’s disease . Parkinsonism Relat. Disord.21 ( 3 ), 317 – 320 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Nyholm D , JanssonR, WillowsT, RemahlIN . Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements . Neurology65 ( 9 ), 1506 – 1507 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Fasano A , LiuLW, PoonYY, LangAE . Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model . Mov. Disord.30 ( 4 ), 598 – 599 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lew MF , SlevinJT, KrügerRet al. Initiation and dose optimization for levodopa-carbidopa intestinal gel: insights from Phase 3 clinical trials . Parkinsonism Relat. Disord.21 ( 7 ), 742 – 748 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Jugel C , EhlenF, TaskinB, MarzinzikF, MullerT, KlostermannF . Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs . PLoS ONE8 ( 6 ), e66639 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D , De La Fuente-FernandezR, ValldeoriolaFet al. Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert . J. Neurol.259 ( 8 ), 1668 – 1672 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lang AE , RodriguezRL, BoydJTet al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials . Mov. Disord. doi:10.1002/mds.26485 ( 2015 ) ( Epub ahead of print ).
   Google Scholar
• Santos-Garcia D , De DeusT, Lopez-PazosEet al. Management of complications related to intraduodenal infusion of levodopa/carbidopa in patients with Parkinson’s disease . Rev. Neurol.58 ( 11 ), 505 – 515 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Salomone G , MaranoM, Di BiaseL, MelgariJM, Di LazzaroV . Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: a serious but preventable complication . Parkinsonism Relat. Disord.21 ( 9 ), 1124 – 1125 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D , MaciasM, LlanezaM, AneirosA . Suicide following duodenal levodopa infusion for Parkinson’s disease . Mov. Disord.24 ( 13 ), 2029 – 2030 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Flisar D AA . Suicide in a PD patient treated with Duodopa – second case . WFN18, S129 ( 2011 ).
   Google Scholar
• Fernandez HH , StandaertDG, ChatamraK, BeneshJA . Reply to letter: suicide in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel . Mov. Disord.30 ( 10 ), 1435 – 1436 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Zorko N , KojovicM, FlisarD, PirtosekZ, KrambergerMG . Suicide in Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel . Mov. Disord.30 ( 10 ), 1434 – 1435 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D , MaciasM, LlanezaM, GrandeM, De La Fuente-FernandezR . Serum vitamin B(12) and folate levels in Parkinson’s disease patients treated with duodenal levodopa infusion . Mov. Disord.26 ( 3 ), 558 – 559 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Onofrj M , BonanniL, CossuG, MancaD, StocchiF, ThomasA . Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment . Parkinsonism Relat. Disord.15 ( Suppl. 3 ), S233 – S236 ( 2009 ).
   PubMedGoogle Scholar
• Manca D , CossuG, MurgiaDet al. Reversible encephalopathy and axonal neuropathy in Parkinson’s disease during duodopa therapy . Mov. Disord.24 ( 15 ), 2293 – 2294 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Skodda S , MullerT . Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa(R) therapy . J. Neural. Transm. (Vienna)120 ( 2 ), 315 – 318 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Urban PP , WellachI, FaissSet al. Subacute axonal neuropathy in Parkinson’s disease with cobalamin and vitamin B6 deficiency under duodopa therapy . Mov. Disord.25 ( 11 ), 1748 – 1752 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Valldeoriola FCA . Infusión intraduodenal de Duodopa . Rev. Neurol.51, 41 – 48 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Uncini A , EleopraR, OnofrjM . Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management . J. Neurol. Neurosurg. Psychiatry86 ( 5 ), 490 – 495 ( 2015 ).
   PubMed Web of Science ®Google Scholar